Resource Summary Report

Generated by RRID on Aug 29, 2026

SW1573

RRID:CVCL_1720
Type: Cell Line

Proper Citation

RRID:CVCL_1720

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1720

Proper Citation: RRID:CVCL_1720

Description: Cell line SW1573 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Minimally invasive lung adenocarcinoma

Defining Citation: PMID:1353703, PMID:1974823, PMID:2566376, PMID:3518877, PMID:6935474, PMID:9256160, PMID:12068308, PMID:20164919, PMID:20215515, PMID:22460905, PMID:24002593, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29444439, PMID:30710758, PMID:30894373, PMID:30971826, PMID:31068700, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., From: Scott and White Clinic; Temple; USA., Part of: NCI RAS program mutant KRAS cell line panel., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SW1573

Synonyms: SW-1573, SW 1573

Cross References: BTO:BTO_0003016, CLO:CLO_0009190, EFO:EFO_0002363, AddexBio:C0016009/4862, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2170, BioGRID_ORCS_Cell_line:1028, BioSample:SAMN03473239,

BioSample:SAMN10988028, cancercelllines:CVCL_1720, Cell_Model_Passport:SIDM01163, ChEMBL-Cells:CHEMBL3307980, ChEMBL-Targets:CHEMBL612570, CLS:305644, Cosmic:724878, Cosmic:1017831, Cosmic:1802305, Cosmic:2060538, Cosmic-CLP:724878, DepMap:ACH-000677, EGA:EGAS00001000610, EGA:EGAS00001000978, EGA:EGAS00001002554, FANTOM5_SSTAR:10708-109H6, GDSC:724878, GEO:GSM206549, GEO:GSM274788, GEO:GSM274818, GEO:GSM385526, GEO:GSM385537, GEO:GSM827193, GEO:GSM887669, GEO:GSM888761, GEO:GSM1670503, IARC_TP53:27581, IGRhCellID:SW1573, LiGeA:CCLE_030, LINCS_LDP:LCL-1799, PharmacoDB:SW1573_1533_2019, PRIDE:PXD011315, PRIDE:PXD030304, Progenetix:CVCL_1720, PubChem_Cell_line:CVCL_1720, Wikidata:Q54971087

ID: CVCL_1720

Record Creation Time: 20220427T221614+0000

Record Last Update: 20260815T235924+0000

Ratings and Alerts

No rating or validation information has been found for SW1573.

No alerts have been found for SW1573.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at RRID .

Fenoglio S, et al. (2026) Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens. Cell reports methods, 6(7), 101470.

Kanemura H, et al. (2026) Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors. Cancer research communications, 6(4), 728.

Sun W, et al. (2026) Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy. Cell reports. Medicine, 7(3), 102644.

Liu Y, et al. (2026) Amphiregulin-mediated EGFR activation drives both intrinsic and acquired resistance to KRAS G12C inhibitors in KRAS G12C-mutant non-small cell lung cancer. Oncogene, 45(31), 3244.

Jameson NM, et al. (2025) The Selective WEE1 Inhibitor Azenosertib Shows Synergistic Antitumor Activity with KRASG12C Inhibitors in Preclinical Models. Cancer research

communications, 5(2), 240.

Feng J, et al. (2025) A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers. Cancer cell.

Wang P, et al. (2025) Glecirasib, a Potent and Selective Covalent KRAS G12C Inhibitor Exhibiting Synergism with Cetuximab or SHP2 Inhibitor JAB-3312. Cancer research communications, 5(5), 792.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Knoll N, et al. (2025) CRISPR-Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer. Cancer research, 85(18), 3518.

Fukuda K, et al. (2024) Targeting WEE1 enhances the antitumor effect of KRAS-mutated non-small cell lung cancer harboring TP53 mutations. Cell reports. Medicine, 5(6), 101578.

Sun F, et al. (2024) Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2. eLife, 12.

Morel M, et al. (2024) FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling. Molecular oncology, 18(3), 762.

Shah A, et al. (2023) Chimeric antibody targeting unique epitope on onco-mucin16 reduces tumor burden in pancreatic and lung malignancies. NPJ precision oncology, 7(1), 74.

Sanidas I, et al. (2022) Chromatin-bound RB targets promoters, enhancers, and CTCF-bound loci and is redistributed by cell-cycle progression. Molecular cell, 82(18), 3333.

Kim JW, et al. (2022) Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Cell reports, 41(1), 111443.

Champagne J, et al. (2021) Oncogene-dependent sloppiness in mRNA translation. Molecular cell, 81(22), 4709.

Pearson JD, et al. (2021) Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer cell, 39(8), 1115.

Hastings JF, et al. (2020) Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. eLife, 9.

Contat C, et al. (2020) Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth. eLife, 9.

Yin N, et al. (2019) Protein Kinase C?? and Wnt/??-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma. Cancer cell, 36(2), 156.